Recombinant human ALK6 (BMPR1B) (149–end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. ALK6 (also known as BMPR1B) is a member of the transmembrane serine/threonine kinase that is the member of the bone morphogenetic protein (BMP) receptor, which is closely related to the activin receptors, ACVR1 and ACVR2. ALK6 is mainly involved in the endochondral bone formation and embryogenesis. ALK6 is expressed in normal and cancerous prostate tissues and used in the endocrine therapy given to prostate cancer patients (1). ALK6 receptor trafficking also plays a significant role in FOP pathogenesis and is used in human T-cell differentiation (2).
ADP-Glo™ Kinase Assay is a luminescent kinase assay that measures ADP formed from a kinase reaction; ADP is converted into ATP, which is a substrate in a reaction catalyzed by Ultra-Glo™ Luciferase that produces light. The luminescent signal positively correlates with ADP amount and kinase activity. The assay is well suited for measuring the effects chemical compounds have on the activity of a broad range of purified kinases, making it ideal for both primary screening as well as kinase selectivity profiling. The ADP-Glo™ Kinase Assay can be used to monitor the activity of virtually any ADP-generating enzyme (e.g., kinase or ATPase) using up to 1mM ATP.
Profile More Compounds In-House: ADP-Glo™ Kinase Assay + Kinase Enzyme System is optimized so that you are up and running in no time. Complete Systems: The Kinase Enzyme Systems include a recombinant kinase enzyme, a substrate appropriate for the enzyme, a reaction buffer, DTT and supplemental reagents as needed. Obtain Reliable Results: The broad dynamic range, the ease of use and better sensitivity obtained with ADP-Glo™ Kinase Assay result in less ambiguous data.
Notes
Kinase Enzyme System manufactured by SignalChem.
Bulk quantities available upon request.
References
1.Ide, H. et al. (1997) Cloning of human bone morphogenetic protein type 1B receptor (BMPR-1B) and its expression in prostate cancer in comparison with other BMPRs. Oncogene 14, 1377–82.
2.Cejalvo, T. et al. (2007) Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development. Immunology 121, 94–104.